menu
    • menu
    [{"orgOrder":0,"company":"Yung Shin Pharm Industrial","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Micafungin","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Yung Shin Pharm Industrial","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yung Shin Pharm Industrial \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Yung Shin Pharm Industrial \/ Undisclosed"},{"orgOrder":0,"company":"Yung Shin Pharm Industrial","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cefoperazone Sodium","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Yung Shin Pharm Industrial","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yung Shin Pharm Industrial \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Yung Shin Pharm Industrial \/ Undisclosed"},{"orgOrder":0,"company":"Yung Shin Pharm Industrial","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Parecoxib Sodium","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase IV","graph3":"Yung Shin Pharm Industrial","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yung Shin Pharm Industrial \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Yung Shin Pharm Industrial \/ Undisclosed"},{"orgOrder":0,"company":"Yung Shin Pharm Industrial","sponsor":"Taichung Veterans General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tenofovir Disoproxil Fumarate","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Yung Shin Pharm Industrial","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Yung Shin Pharm Industrial \/ Taichung Veterans General Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Yung Shin Pharm Industrial \/ Taichung Veterans General Hospital"},{"orgOrder":0,"company":"Yung Shin Pharm Industrial","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"TAIWAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Yung Shin Pharm Industrial","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Yung Shin Pharm Industrial \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yung Shin Pharm Industrial \/ Undisclosed"},{"orgOrder":0,"company":"Yung Shin Pharm Industrial","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palonosetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Yung Shin Pharm Industrial","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yung Shin Pharm Industrial \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Yung Shin Pharm Industrial \/ Undisclosed"},{"orgOrder":0,"company":"Yung Shin Pharm Industrial","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Vaway","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Yung Shin Pharm Industrial","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yung Shin Pharm Industrial \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Yung Shin Pharm Industrial \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Yung Shin Pharm Industrial

    Menu

    Yung Shin Pharm Industrial

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Yung Shin Pharm Industrial

                            Taiwan arrow
                            Pharma MES 2025
                            Not Confirmed

                            Yung Shin Pharm Industrial

                            Taiwan arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Parecoxib Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence of Two Formulations of Parecoxib in Healthy Volunteers Under Fasting Conditions

                            Details : Parecoxib is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pain, Postoperative.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 19, 2024

                            Lead Product(s) : Parecoxib Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Yung Shin Pharm Industrial

                            Taiwan arrow
                            Pharma MES 2025
                            Not Confirmed

                            Yung Shin Pharm Industrial

                            Taiwan arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risperidone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate RCN3028 in Treatment of Drug-Induced VMS in Breast Cancer

                            Details : RCN3028 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hot Flashes.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 08, 2023

                            Lead Product(s) : Risperidone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Yung Shin Pharm Industrial

                            Taiwan arrow
                            Pharma MES 2025
                            Not Confirmed

                            Yung Shin Pharm Industrial

                            Taiwan arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cefoperazone Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate Bioequivalence of Burotam (1/1 g/Vial)

                            Details : Cefoperazone is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Communicable Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 16, 2022

                            Lead Product(s) : Cefoperazone Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Yung Shin Pharm Industrial

                            Taiwan arrow
                            Pharma MES 2025
                            Not Confirmed

                            Yung Shin Pharm Industrial

                            Taiwan arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Micafungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate Bioequivalence of Micafungin (50mg/Vial)

                            Details : Micafungin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Candidiasis, Invasive.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 11, 2022

                            Lead Product(s) : Micafungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Yung Shin Pharm Industrial

                            Taiwan arrow
                            Pharma MES 2025
                            Not Confirmed

                            Yung Shin Pharm Industrial

                            Taiwan arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tenofovir Disoproxil Fumarate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Sponsor : Taichung Veterans General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics of Two Formulation of Tenofovir Disoproxil Fumarate

                            Details : Tenofovir Disoproxil Fumarate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 17, 2020

                            Lead Product(s) : Tenofovir Disoproxil Fumarate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Sponsor : Taichung Veterans General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Yung Shin Pharm Industrial

                            Taiwan arrow
                            Pharma MES 2025
                            Not Confirmed

                            Yung Shin Pharm Industrial

                            Taiwan arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Palonosetron

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate Bioequivalence of Palonosetron (0.25mg/5mL)

                            Details : Palonosetron is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Chemotherapy-induced Nausea and Vomiting.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 14, 2020

                            Lead Product(s) : Palonosetron

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Yung Shin Pharm Industrial

                            Taiwan arrow
                            Pharma MES 2025
                            Not Confirmed

                            Yung Shin Pharm Industrial

                            Taiwan arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vaway

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate Bioequivalence of Voriconazole(200mg/Vial) .

                            Details : Vaway is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 17, 2020

                            Lead Product(s) : Vaway

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth